Co-targeting TGF-β and PD-L1 with radiation therapy: The Goldilocks principle

Abstract

In the current issue of Cancer Cell , Lan et al. 1 demonstrate that a bifunctional fusion protein targeting TGF-β and PD-L1 can synergize with radiation therapy to simultaneously augment tumor control and reduce normal tissue toxicity.

The TGF-β Family in Glioblastoma

“…In comparison with monotherapies, some preclinical studies in mouse models have shown efficacy in the use of molecules that target both PD-L1 and TGF-β. M7824 suppresses tumor growth, metastasis, extends survival, and confers long-term protective antitumor immunity (evaluated in multiple tumor types) [144,145]. M7824 has shown a favorable safety profile and clinical efficacy in phase 1 clinical trials, including patients with advanced solid tumors, NSCLC, recurrent GBM, cervical cancer, metastatic TNBC, heavily pretreated CRC, or human papillomavirus (HPV)-associated cancers [132].…”